225 related articles for article (PubMed ID: 12631714)
21. Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41.
Ashkenazi A; Viard M; Wexler-Cohen Y; Blumenthal R; Shai Y
FASEB J; 2011 Jul; 25(7):2156-66. PubMed ID: 21429941
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
23. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.
Gustchina E; Louis JM; Bewley CA; Clore GM
J Mol Biol; 2006 Dec; 364(3):283-9. PubMed ID: 17010381
[TBL] [Abstract][Full Text] [Related]
24. Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.
Gallo SA; Reeves JD; Garg H; Foley B; Doms RW; Blumenthal R
Retrovirology; 2006 Dec; 3():90. PubMed ID: 17144914
[TBL] [Abstract][Full Text] [Related]
25. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.
Dimitrov AS; Louis JM; Bewley CA; Clore GM; Blumenthal R
Biochemistry; 2005 Sep; 44(37):12471-9. PubMed ID: 16156659
[TBL] [Abstract][Full Text] [Related]
26. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion.
Ablan S; Rawat SS; Viard M; Wang JM; Puri A; Blumenthal R
Virol J; 2006 Dec; 3():104. PubMed ID: 17187670
[TBL] [Abstract][Full Text] [Related]
27. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
[TBL] [Abstract][Full Text] [Related]
28. Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.
Baldwin CE; Berkhout B
Retrovirology; 2006 Nov; 3():84. PubMed ID: 17134507
[TBL] [Abstract][Full Text] [Related]
29. Identification of the HIV-1 gp41 core-binding motif--HXXNPF.
Huang JH; Liu ZQ; Liu S; Jiang S; Chen YH
FEBS Lett; 2006 Sep; 580(20):4807-14. PubMed ID: 16904109
[TBL] [Abstract][Full Text] [Related]
30. Conserved arginine residue in the membrane-spanning domain of HIV-1 gp41 is required for efficient membrane fusion.
Long Y; Meng F; Kondo N; Iwamoto A; Matsuda Z
Protein Cell; 2011 May; 2(5):369-76. PubMed ID: 21667332
[TBL] [Abstract][Full Text] [Related]
31. The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion.
Chien MP; Jiang S; Chang DK
FASEB J; 2008 Apr; 22(4):1179-92. PubMed ID: 18032634
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.
Earl PL; Moss B
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):589-94. PubMed ID: 8369163
[TBL] [Abstract][Full Text] [Related]
33. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
34. Exploring the membrane fusion mechanism through force-induced disassembly of HIV-1 six-helix bundle.
Gao K; Zhang Y; Lou J
Biochem Biophys Res Commun; 2016 May; 473(4):1185-1190. PubMed ID: 27079239
[TBL] [Abstract][Full Text] [Related]
35. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
36. Normal T cell receptor-mediated signaling in T cell lines stably expressing HIV-1 envelope glycoproteins.
Tani Y; Tian H; Lane HC; Cohen DI
J Immunol; 1993 Dec; 151(12):7337-48. PubMed ID: 7903106
[TBL] [Abstract][Full Text] [Related]
37. A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex.
Jacobs A; Quraishi O; Huang X; Bousquet-Gagnon N; Nault G; Francella N; Alvord WG; Pham N; Soucy C; Robitaille M; Bridon D; Blumenthal R
J Biol Chem; 2007 Nov; 282(44):32406-13. PubMed ID: 17726011
[TBL] [Abstract][Full Text] [Related]
38. Imaging individual retroviral fusion events: from hemifusion to pore formation and growth.
Melikyan GB; Barnard RJ; Abrahamyan LG; Mothes W; Young JA
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8728-33. PubMed ID: 15937118
[TBL] [Abstract][Full Text] [Related]
39. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
Soonthornsata B; Tian YS; Utachee P; Sapsutthipas S; Isarangkura-na-Ayuthaya P; Auwanit W; Takagi T; Ikuta K; Sawanpanyalert P; Kawashita N; Kameoka M
Virology; 2010 Sep; 405(1):157-64. PubMed ID: 20580393
[TBL] [Abstract][Full Text] [Related]
40. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
